ELECTROMAGNETIC FIELD THERAPY DELAYS CELLULAR SENESCENCE AND DEATH BY ENHANCEMENT OF THE HEAT SHOCK RESPONSE

• US 20090276019A1
• Filed: 03/19/2009
• Published: 11/05/2009
• Est. Priority Date: 03/19/2008
• Status: Active Grant

• Current Assignee: Board of Trustees of The University of Illinois
• Original Assignee: Board of Trustees of The University of Illinois
• Inventors: Zhou, Ximing, Perez, Felipe Pablo, Jurivich, Donald A., Morisaki, Jorge Javier
• Granted Patent: US 9,014,801 B2
• Time in Patent Office: Days
• US Class Current: 607/115
• CPC Class Codes: A61N 1/403 for thermotherapy, e.g. hyperthermia
• CPC Class Codes: A61N 5/02 using microwaves
• CPC Class Codes: C12N 13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Abstract

Disclosed herein is a method comprising repetitive electromagnetic field shock to at least one living cell, wherein the repetitive electromagnetic field shock improves HSF1 and/or HSR function, and producing delaying and reversal of aging and age related diseases. Also disclosed herein is an apparatus adapted to deliver repetitive electromagnetic field shock to at least one living cell, wherein the repetitive electromagnetic field shock improves HSF1 and HSR function.

Claims

1. A method comprising:

applying repetitive electromagnetic field shock to at least one living cell, wherein the repetitive electromagnetic field shock is configured to improve either HSF1 or HSR function, or HSF1 and HSR function, without initiating a classical heat shock response.

2. The method of claim 1, wherein the application of the repetitive electromagnetic field shock is configured to disrupt the molecular brake of HSF1-DNA binding without resulting in a decline of Hsp90.

3. The method of claim 1, wherein the applying repetitive electromagnetic field shock is at about 50 MHz/0.5 W continuous radiation.

4. The method of claim 1, wherein the applying repetitive electromagnetic shock is between about 5 minutes to about 30 minutes in duration and is repeated for a period selected from the group consisting of:

once a day, about once every two days, about once every three days, about once a week, and about twice a week.

6. The method of claim 1, wherein the applying repetitive electromagnetic field shock delays or reverses the aging process or at least one age related disease.

7. The method of claim 1, wherein the repetitive electromagnetic field shock is applied to the at least one cell until the cell reaches cellular senescence.

8. The method of claim 1, wherein the at least one cell is a T cell.

9. The method of claim 1, wherein the at least one living cell is a plurality of living cells, and the method further comprises applying repetitive electromagnetic field shock to a plurality of in vivo living cells.

10. The method of claim 9, wherein the in vivo living cells are brain cells.

11. The method of claim 1, wherein the repetitive electromagnetic field shock is delivered to at least a localized region of the body of a patient.

12. The method of claim 1, wherein the repetitive electromagnetic field shock is provided by a transversal electromagnetic chamber.

13. The method of claim 1, wherein the at least one living cell is a plurality of living cells and the applying repetitive electromagnetic field shock extends the replicative lifespan of the at least one living cell.

14. The method of claim 13, wherein the applying repetitive electromagnetic field shock extends the terminal lifespan of at least one living cell of the plurality of living cells.

15. The method of claim 1, wherein the at least one living cell is a plurality of living fibroblast cells and the applying repetitive electromagnetic field shock delays the average age-related enlargement and diversification of at least one fibroblast cell.

16. The method of claim 1, wherein the at least one living cell is a plurality of living fibroblast cells and the applying repetitive electromagnetic field shock reverts at least one fibroblast cell to a more youthful phenotype.

17. The method of claim 6, wherein the at least one living cell is a plurality of T-cells and at least a portion of the applying repetitive electromagnetic field shock is applied to the T-cells during IL-2 stimulation.

18. The method of claim 6, wherein at least a portion of the application of the repetitive electromagnetic field shock is applied concurrently with a treatment that augments the DAF-16 (FOXO) pathway.

19. A product comprising:

an apparatus having a power source operatively connected to an electromagnetic fields source and at least one directional coupler, wherein the apparatus is configurable to transmit repetitive electromagnetic field shock at about 50 MHz/0.5 W continuous radiation; and

instructions for operating said apparatus, that if executed, indicate an orientation of at least a portion of a patient'"'"'s body in relation to the at least one directional coupler during the transmission of the continuous radiation to improve either HSF1 or HSR function, or HSF1 and HSR function, of target cells within said portion of the patient'"'"'s body, without initiating a classical heat shock response.

20. The product of claim 19, wherein the instructions provide at least one treatment protocol, wherein the at least one protocol provides an indication for transmitting the continuous radiation for a first time duration and a second time duration, wherein the first and the second time durations are at least about 1 day apart.

21. The product of claim 19, wherein the instructions provide an indication that the transmission of the continuous radiation from the apparatus will disrupt the molecular brake of HSF1-DNA binding without resulting in a decline of Hsp90.

22. The product of claim 19, wherein the instructions provide an indication that the transmission of the continuous radiation from the apparatus will extends the replicative lifespan of the at least one living cell within the portion of the patient'"'"'s body.

23. The product of claim 19, wherein the instructions provide an indication that the transmission of the continuous radiation from the apparatus will delay the average age-related enlargement and diversification of at least one living cell or reverts at least one living cell to a more youthful phenotype within the portion of the patient'"'"'s body.